Daniel Ezzat

Daniel Ezzat

Auto-generated profile, based on publicly available information

Daniel Ezzat

Heart and Vascular Institute, Mass General Brigham, Boston (D.E., M.A.P., L.L., A.C., N.D.M., Z.Y., S.M.J.C., P.N., J.D.R., R.A.H., S.M., M.C.H.).

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
HGHenri Gruwez
Henri Gruwez
DEDaniel Ezzat
Daniel Ezzat
TPTim Van Puyvelde
Tim Van Puyvelde
SDSebastiaan Dhont
Sebastiaan Dhont
EMEvelyne Meekers
Evelyne Meekers
LPLaurent Pison
Laurent Pison
Photoplethysmography- (PPG) based smartphone applications facilitate heart rate and rhythm monitoring in patients with paroxysmal and persistent atrial fibrillation (AF). Despite an endorsement from the European Heart Rhythm Association, validation studies in this setting are lacking. Therefore, we evaluated the accuracy of PPG-derived heart rate and rhythm classification in subjects with an established diagnosis of AF in unsupervised real-world conditions. Fifty consecutive patients were enrolled, 4 weeks before undergoing AF ablation. Patients used a handheld single-lead electrocardiography (ECG) device and a fingertip PPG smartphone application to record 3907 heart rhythm measurements twice daily during 8 weeks. The ECG was performed immediately before and after each PPG recording and was given a diagnosis by the majority of three blinded cardiologists. A consistent ECG diagnosis was exhibited along with PPG data of sufficient quality in 3407 measurements. A single measurement exhibited good quality more often with ECG (93.2%) compared to PPG (89.5%; P < 0.001). However, PPG signal quality improved to 96.6% with repeated measurements. Photoplethysmography-based detection of AF demonstrated excellent sensitivity [98.3%; confidence interval (CI): 96.7–99.9%], specificity (99.9%; CI: 99.8–100.0%), positive predictive value (99.6%; CI: 99.1–100.0%), and negative predictive value (99.6%; CI: 99.0–100.0%). Photoplethysmography underestimated the heart rate in AF with 6.6 b.p.m. (95% CI: 5.8 b.p.m. to 7.4 b.p.m.). Bland–Altman analysis revealed increased underestimation in high heart rates. The root mean square error was 11.8 b.p.m. Smartphone applications using PPG can be used to monitor patients with AF in unsupervised real-world conditions. The accuracy of AF detection algorithms in this setting is excellent, but PPG-derived heart rate may tend to underestimate higher heart rates.

27 August 2025 in JACC
Verified
Journal Article
Open access
DEDaniel Ezzat
Daniel Ezzat
MUMesbah Uddin
Mesbah Uddin
LXLiying Xue
Liying Xue
YPYash Pershad
Yash Pershad
SZShengruo Zhang
Shengruo Zhang
MHMichael C. Honigberg
Michael C. Honigberg
Clonal hematopoiesis of indeterminate potential (CHIP) is an emerging aging-related risk factor for cardiovascular disease (CVD). However, previous studies suggest that CHIP's relevance to CVD may diminish with advancing age. This study aimed to test the association of CHIP and its key subtypes with incident CVD in an older population. Participants in the Women's Health Initiative Long Life Study completed study assessments in 2012-2013 and underwent high-coverage sequencing (median depth 4,580×). The co-primary exposures were composite CHIP and TET2 CHIP. DNMT3A, ASXL1, JAK2, and non-DNMT3A CHIP were examined as secondary exposures. The primary outcome was incident coronary heart disease. Secondary outcomes were incident heart failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF), ischemic stroke, venous thromboembolism, and cardiovascular death. Multivariable-adjusted Cox models tested associations between CHIP and incident CVD. Among 6,677 women (median age 80 years; median follow-up 10.1 years), 2,176 (32.6%) had any CHIP. TET2 CHIP was independently associated with incident coronary heart disease (aHR: 1.36 [95% CI: 1.05-1.77]; P = 0.02), whereas composite CHIP was not (aHR: 1.07 [95% CI: 0.89-1.28]; P = 0.49). Secondarily, TET2 CHIP was associated with HFpEF (aHR: 1.40 [95% CI: 1.03-1.90]; P = 0.03), ASXL1 CHIP with HFrEF (aHR: 3.16 [95% CI: 1.53-6.55]; P = 0.002), and JAK2 CHIP with ischemic stroke (aHR: 2.49 [95% CI: 1.17-5.30]; P = 0.02), venous thromboembolism (aHR: 2.71 [95% CI: 1.11-6.65]; P = 0.03), and cardiovascular death (aHR: 2.62 [95% CI: 1.68-4.11]; P < 0.001). No other significant associations were observed for composite or DNMT3A CHIP. In an older female cohort, key CHIP subtypes (TET2, ASXL1, and JAK2) were associated with incident CVD, with associations that appeared to differ by CVD outcome. These findings suggest that CHIP remains associated with cardiovascular health into later life. (Women's Health Initiative [WHI]; NCT00000611).

28 March 2026 in European Heart Journal
Verified
Journal Article
Open access
DEDaniel Ezzat
Daniel Ezzat
DLDiana M Lopez
Diana M Lopez
BCBrian L Claggett
Brian L Claggett
LLLinke Li
Linke Li
NMNiekbachsh Mohammadnia
Niekbachsh Mohammadnia
MHMichael C Honigberg
Michael C Honigberg
Background and Aims: Elevated lipoprotein(a) [Lp(a)] levels are an established risk factor for atherosclerotic cardiovascular disease, but the association between Lp(a) and venous thromboembolism (VTE) remains unclear. Sex and hormonal status may modify the relationship between Lp(a) and VTE. Methods: The present study included participants from the UK Biobank with available baseline Lp(a) data. Individuals with a history of VTE or cancer, as well as those using anticoagulants, were excluded. Multivariable-adjusted Cox models were used to assess the association between Lp(a) levels ≥125 nmol/L and incident VTE in premenopausal women, postmenopausal women, and men. Subgroup analyses stratified premenopausal women by oral contraceptive (OCP) use and postmenopausal women by menopausal hormone therapy (MHT) use. Results: Among 55 302 premenopausal women, 129 045 postmenopausal women, and 189 013 men, the proportions with Lp(a) ≥ 125 nmol/L were 14.0%, 19.0%, and 15.0%, respectively. Over a median (interquartile range) follow-up of 13.6 (12.9–14.4) years, 8186 VTE events occurred (cumulative incidence 2.2%). Lp(a) ≥ 125 nmol/L was associated with incident VTE in premenopausal women [adjusted hazard ratio (aHR) 1.32; 95% confidence interval (CI) 1.04–1.66; P = .02] but not in postmenopausal women (aHR 1.03; 95% CI 0.94–1.13; P = .47; Pinteraction = .03) or men (aHR 1.00; 95% CI 0.92–1.08; P = .94). OCP use did not modify the Lp(a)-VTE association among premenopausal women (Pinteraction = .61). However, among postmenopausal MHT users, Lp(a) ≥ 125 nmol/L was associated with higher VTE risk (aHR 1.48; 95% CI 1.03–2.12; P = .03; Pinteraction = .04). Conclusions: Elevated Lp(a) was associated with VTE in premenopausal women and in postmenopausal MHT users, suggesting that hormonal context may influence Lp(a)-associated thrombotic risk.

10 June 2026 in Nature
Verified
Journal Article
Closed access
TGTeresa Gerhardt
Teresa Gerhardt
WJWalter Jacob
Walter Jacob
LGLena Gaebel
Lena Gaebel
MHMerlin Heiser
Merlin Heiser
CWChristopher Wolfram
Christopher Wolfram
CMCameron S. McAlpine
Cameron S. McAlpine

30 August 2026 in European Heart Journal
Verified
Journal Article
Closed access
ACAnnie Chang
Annie Chang
LLLinke Li
Linke Li
DEDaniel Ezzat
Daniel Ezzat
SFSpencer Flynn
Spencer Flynn
NMNore De Moor
Nore De Moor
MHMichael C Honigberg
Michael C Honigberg
Background and Aims: The cardiovascular-kidney-metabolic (CKM) syndrome framework integrates the shared pathophysiology of cardiovascular disease, excess adiposity, diabetes, and chronic kidney disease into a unified staging framework. Clonal haematopoiesis of indeterminate potential (CHIP), the age-related expansion of hematopoietic stem cells harbouring somatic mutations, has been linked to several CKM components, but its relationship with CKM syndrome is unknown. Methods: UK Biobank participants without a history of hematologic malignancy were included. Exposures included any CHIP, large CHIP, and major gene-specific CHIP subtypes. Outcomes were CKM stage and progression to stage 4 CKM syndrome during follow-up. Associations of CHIP with CKM stage and progression were tested using multivariable-adjusted logistic and Cox regression, respectively. Proteomic mediation analyses prioritized circulating proteins associated with CKM progression. Results: Among 451,460 participants (mean [SD] age, 56.5 [8.1] years; 245,055 females [54.3%]), 15,486 (3.4%) had CHIP. CHIP was associated with higher CKM stage, driven by associations with non-DNMT3A CHIP, including TET2 (adjusted OR [aOR], 1.10; 95% CI, 1.00-1.20; false discovery rate [FDR]-corrected P = 0.045) and JAK2 CHIP (aOR, 1.68; 95% CI, 1.20-2.35; FDR-corrected P = 0.003). Over a median (IQR) 13.5 (12.6-14.3) years of follow-up, CHIP was independently associated with progression to stage 4 CKM, again driven by associations with non-DNMT3A CHIP subtypes (aHR, 1.24; 95% CI, 1.17-1.31; FDR-corrected P < 0.001). Proteomic mediators of progression to stage 4 CKM in non-DNMT3A CHIP were enriched for immune and inflammatory signalling pathways. Conclusion: These findings identify non-DNMT3A CHIP as a marker of CKM progression and support inflammatory mechanisms linking CHIP to CKM syndrome.

1 June 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ACAnnie Chang
Annie Chang
DEDaniel Ezzat
Daniel Ezzat
MUMesbah Uddin
Mesbah Uddin
YPYash Pershad
Yash Pershad
JCJason M. Collins
Jason M. Collins
MHMichael C. Honigberg
Michael C. Honigberg
Clonal hematopoiesis of indeterminate potential (CHIP) represents the age-related expansion of hematopoietic stem cells with preleukemic mutations. However, its association with all-cause and cause-specific mortality has not been well characterized in older adults. We aimed to evaluate whether CHIP is associated with all-cause and cause-specific mortality in a population of older women in the United States. Our study included 6,704 participants in the Women’s Health Initiative Long Life Study (WHI-LLS) without hematologic malignancy. The co-primary exposures were any CHIP (variant allele frequency [VAF] ≥ 2%) and large CHIP (VAF ≥ 10%), and the primary outcome was all-cause mortality. Multivariable-adjusted Cox proportional hazards models tested the associations of CHIP and CHIP subtypes with all-cause and cause-specific mortality. Any CHIP and large CHIP were independently associated with all-cause mortality, with multivariable-adjusted hazard ratios (aHRs) of 1.12 (95% confidence interval [CI] 1.04-1.21; P = 0.003) and 1.28 (95% CI 1.15-1.43; P < 0.001), respectively. In gene-specific analyses, non- DNMT3A CHIP was associated with all-cause mortality (aHR: 1.22 [95% CI: 1.12-1.34], P < 0.001), while DNMT3A CHIP was not (aHR: 1.07 [95% CI: 0.98-1.18], P = 0.13). Furthermore, large CHIP was associated with cardiovascular (aHR: 1.29 [95% CI: 1.08-1.55], P = 0.006), cancer (aHR: 1.49 [95% CI: 1.11-2.02], P = 0.009), and neurologic (aHR: 1.40 [95% CI: 1.07-1.84], P = 0.02) death. In this cohort of older women, CHIP, particularly large clones and non- DNMT3A CHIP, was associated with all-cause and cause-specific mortality. These findings suggest that clonal size and subtype may differentially influence mortality risk.